Cargando…
Plain language summary: does treatment with vibegron result in improvements in overactive bladder (OAB) symptoms that are meaningful to people with OAB?
WHAT IS THIS SUMMARY ABOUT? This is a plain language summary of an article published in the journal Advances in Therapy. In 2020, the US Food and Drug Administration (also called the FDA) approved a medicine called vibegron to treat overactive bladder, also called OAB. The key results used to approv...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Becaris Publishing Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690438/ https://www.ncbi.nlm.nih.gov/pubmed/37586052 http://dx.doi.org/10.57264/cer-2023-0049 |
_version_ | 1785152526718337024 |
---|---|
author | Frankel, Jeffrey Staskin, David Varano, Susann Newman, Diane K Gregg, Steven G Owens-Grillo, Janet |
author_facet | Frankel, Jeffrey Staskin, David Varano, Susann Newman, Diane K Gregg, Steven G Owens-Grillo, Janet |
author_sort | Frankel, Jeffrey |
collection | PubMed |
description | WHAT IS THIS SUMMARY ABOUT? This is a plain language summary of an article published in the journal Advances in Therapy. In 2020, the US Food and Drug Administration (also called the FDA) approved a medicine called vibegron to treat overactive bladder, also called OAB. The key results used to approve vibegron were from the EMPOWUR study. In the EMPOWUR study, participants who took vibegron had fewer urination episodes, urgency episodes, and bladder leaks each day than those who took a pill containing no medicine, called a placebo. At the end of the study, participants also rated how much their overactive bladder symptoms changed overall during EMPOWUR by responding to a survey. Many participants rated their overactive bladder symptoms as improved overall. This study asked if improvements in the number of urination episodes, urgency episodes, and bladder leaks caused by urgency were associated with feeling better overall. This study also looked at how many participants in the EMPOWUR study had improvements in the number of urination episodes, urgency episodes, and bladder leaks that were big enough to matter. A separate group of people with overactive bladder were asked about the magnitude of improvements that would be important to them. This group had not participated in the EMPOWUR study. WHAT WERE THE RESULTS? EMPOWUR participants who reported that taking medicine resulted in their overactive bladder symptoms getting better overall also generally reported fewer daily urinations, urgency episodes, and bladder leaks after treatment. Many had changes in their symptoms that were meaningful. Meaningful was defined for each symptom as: at least 15% fewer urinations, 50% fewer urgency episodes, and 75% fewer bladder leaks. Participants who received vibegron had meaningful reductions in the daily number of episodes of urination, urgency, and bladder leaks more often than those who received the placebo (pill with no active medicine). People with overactive bladder who did not participate in the study were interviewed and said that improvements to those symptoms, similar to those seen in the EMPOWUR study, would be important to them. WHAT DO THE RESULTS MEAN? This study suggests that the results we measured in the EMPOWUR study may also reflect changes in overactive bladder symptoms that are big enough to be important to people with overactive bladder. Many participants who took vibegron in the EMPOWUR study felt that it helped to improve their individual overactive bladder symptoms. This may also help improve quality of life of participants. Clinical Trial Registration: NCT03492281 (ClinicalTrials.gov) |
format | Online Article Text |
id | pubmed-10690438 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Becaris Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-106904382023-12-02 Plain language summary: does treatment with vibegron result in improvements in overactive bladder (OAB) symptoms that are meaningful to people with OAB? Frankel, Jeffrey Staskin, David Varano, Susann Newman, Diane K Gregg, Steven G Owens-Grillo, Janet J Comp Eff Res Plain Language Summary of Publication WHAT IS THIS SUMMARY ABOUT? This is a plain language summary of an article published in the journal Advances in Therapy. In 2020, the US Food and Drug Administration (also called the FDA) approved a medicine called vibegron to treat overactive bladder, also called OAB. The key results used to approve vibegron were from the EMPOWUR study. In the EMPOWUR study, participants who took vibegron had fewer urination episodes, urgency episodes, and bladder leaks each day than those who took a pill containing no medicine, called a placebo. At the end of the study, participants also rated how much their overactive bladder symptoms changed overall during EMPOWUR by responding to a survey. Many participants rated their overactive bladder symptoms as improved overall. This study asked if improvements in the number of urination episodes, urgency episodes, and bladder leaks caused by urgency were associated with feeling better overall. This study also looked at how many participants in the EMPOWUR study had improvements in the number of urination episodes, urgency episodes, and bladder leaks that were big enough to matter. A separate group of people with overactive bladder were asked about the magnitude of improvements that would be important to them. This group had not participated in the EMPOWUR study. WHAT WERE THE RESULTS? EMPOWUR participants who reported that taking medicine resulted in their overactive bladder symptoms getting better overall also generally reported fewer daily urinations, urgency episodes, and bladder leaks after treatment. Many had changes in their symptoms that were meaningful. Meaningful was defined for each symptom as: at least 15% fewer urinations, 50% fewer urgency episodes, and 75% fewer bladder leaks. Participants who received vibegron had meaningful reductions in the daily number of episodes of urination, urgency, and bladder leaks more often than those who received the placebo (pill with no active medicine). People with overactive bladder who did not participate in the study were interviewed and said that improvements to those symptoms, similar to those seen in the EMPOWUR study, would be important to them. WHAT DO THE RESULTS MEAN? This study suggests that the results we measured in the EMPOWUR study may also reflect changes in overactive bladder symptoms that are big enough to be important to people with overactive bladder. Many participants who took vibegron in the EMPOWUR study felt that it helped to improve their individual overactive bladder symptoms. This may also help improve quality of life of participants. Clinical Trial Registration: NCT03492281 (ClinicalTrials.gov) Becaris Publishing Ltd 2023-08-10 /pmc/articles/PMC10690438/ /pubmed/37586052 http://dx.doi.org/10.57264/cer-2023-0049 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Plain Language Summary of Publication Frankel, Jeffrey Staskin, David Varano, Susann Newman, Diane K Gregg, Steven G Owens-Grillo, Janet Plain language summary: does treatment with vibegron result in improvements in overactive bladder (OAB) symptoms that are meaningful to people with OAB? |
title | Plain language summary: does treatment with vibegron result in improvements in overactive bladder (OAB) symptoms that are meaningful to people with OAB? |
title_full | Plain language summary: does treatment with vibegron result in improvements in overactive bladder (OAB) symptoms that are meaningful to people with OAB? |
title_fullStr | Plain language summary: does treatment with vibegron result in improvements in overactive bladder (OAB) symptoms that are meaningful to people with OAB? |
title_full_unstemmed | Plain language summary: does treatment with vibegron result in improvements in overactive bladder (OAB) symptoms that are meaningful to people with OAB? |
title_short | Plain language summary: does treatment with vibegron result in improvements in overactive bladder (OAB) symptoms that are meaningful to people with OAB? |
title_sort | plain language summary: does treatment with vibegron result in improvements in overactive bladder (oab) symptoms that are meaningful to people with oab? |
topic | Plain Language Summary of Publication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690438/ https://www.ncbi.nlm.nih.gov/pubmed/37586052 http://dx.doi.org/10.57264/cer-2023-0049 |
work_keys_str_mv | AT frankeljeffrey plainlanguagesummarydoestreatmentwithvibegronresultinimprovementsinoveractivebladderoabsymptomsthataremeaningfultopeoplewithoab AT staskindavid plainlanguagesummarydoestreatmentwithvibegronresultinimprovementsinoveractivebladderoabsymptomsthataremeaningfultopeoplewithoab AT varanosusann plainlanguagesummarydoestreatmentwithvibegronresultinimprovementsinoveractivebladderoabsymptomsthataremeaningfultopeoplewithoab AT newmandianek plainlanguagesummarydoestreatmentwithvibegronresultinimprovementsinoveractivebladderoabsymptomsthataremeaningfultopeoplewithoab AT greggsteveng plainlanguagesummarydoestreatmentwithvibegronresultinimprovementsinoveractivebladderoabsymptomsthataremeaningfultopeoplewithoab AT owensgrillojanet plainlanguagesummarydoestreatmentwithvibegronresultinimprovementsinoveractivebladderoabsymptomsthataremeaningfultopeoplewithoab |